Adolescent Male Human Papillomavirus Vaccination

Overview

Journal Glob Pediatr Health

Specialty Pediatrics

Date 2016 Jun 24

PMID 27336012

Citations 6

Authors

Vivian C Nanagas

Adrienne Stolfi

Maria T Nanagas

Gregory M Eberhart

Sherman J Alter

Affiliations

Soon will be listed here.

Abstract

Objective. To determine male vaccination rates with quadrivalent human papillomavirus vaccine (HPV4) before and after the October 2011 national recommendation to routinely immunize adolescent males. Methods. We reviewed HPV4 dose 1 (HPV4-1) uptake in 292 adolescent males in our urban clinic prior to national recommendations and followed-up for HPV4 series completion rates. After national recommendation, 248 urban clinic and 247 suburban clinic males were reviewed for HPV4-1 uptake. Factors associated with HPV4-1 refusal were determined with multiple logistic regression. Results. Of the initial 292 males, 78% received HPV4-1 and 38% received the 3-dose series. After recommendation, HPV4-1 uptake was 59% and 7% in urban and suburban clinics, respectively. Variables associated with HPV4-1 uptake/refusal included time period, race, type of insurance, and receipt of concurrent vaccines. Conclusions. HPV4-1 vaccination rates in our urban clinic were high before and after routine HPV vaccine recommendations for adolescent males. Our vaccination rates were much higher than in a suburban practice.

Citing Articles

Area-Level Variation and Human Papillomavirus Vaccination among Adolescents and Young Adults in the United States: A Systematic Review.

Do E, Rossi B, Miller C, Ksinan A, Wheeler D, Chukmaitov A Cancer Epidemiol Biomarkers Prev. 2020; 30(1):13-21.

PMID: 33008874 PMC: 8108385. DOI: 10.1158/1055-9965.EPI-20-0617.

Why human papilloma virus vaccination coverage is low among adolescents in the US? A study of barriers for vaccination uptake.

Sriram S, Ranganathan R J Family Med Prim Care. 2019; 8(3):866-870.

PMID: 31041215 PMC: 6482788. DOI: 10.4103/jfmpc.jfmpc_107_19.

Prevalence and incidence of anal human papillomavirus infection in Mexican men: Need for universal prevention policies.

Posso H, Leon-Maldonado L, Allen-Leigh B, Salmeron J, Quiterio M, Giuliano A Salud Publica Mex. 2019; 60(6):645-652.

PMID: 30699269 PMC: 6642746. DOI: 10.21149/8454.

HPV vaccine recommendation profiles among a national network of pediatric practitioners: understanding contributors to parental vaccine hesitancy and acceptance.

Hopfer S, Wright M, Pellman H, Wasserman R, Fiks A Hum Vaccin Immunother. 2018; 15(7-8):1776-1783.

PMID: 30570419 PMC: 6746469. DOI: 10.1080/21645515.2018.1560771.

HPV vaccination in boys: Determining the clinical relevance of this strategy.

Zur Hausen H, Mammas I, Spandidos D Exp Ther Med. 2017; 14(4):3327-3328.

PMID: 29042912 PMC: 5639420. DOI: 10.3892/etm.2017.5005.

References

Smith P, Chu S, Barker L . Children who have received no vaccines: who are they and where do they live?. Pediatrics. 2004; 114(1):187-95. DOI: 10.1542/peds.114.1.187. View

Slade B, Leidel L, Vellozzi C, Woo E, Hua W, Sutherland A . Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009; 302(7):750-7. DOI: 10.1001/jama.2009.1201. View

Pomfret T, Gagnon Jr J, Gilchrist A . Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther. 2011; 36(1):1-9. DOI: 10.1111/j.1365-2710.2009.01150.x. View

. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011; 60(50):1705-8. View

Kempe A, Daley M, McCauley M, Crane L, Suh C, Kennedy A . Prevalence of parental concerns about childhood vaccines: the experience of primary care physicians. Am J Prev Med. 2011; 40(5):548-55. DOI: 10.1016/j.amepre.2010.12.025. View

Georgousakis M, Jayasinghe S, Brotherton J, Gilroy N, Chiu C, Macartney K . Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infect Dis. 2012; 12(8):627-34. DOI: 10.1016/S1473-3099(12)70031-2. View

. National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011. MMWR Morb Mortal Wkly Rep. 2012; 61(34):671-7. View

Rand C, Schaffer S, Humiston S, Albertin C, Shone L, Heintz E . Patient-provider communication and human papillomavirus vaccine acceptance. Clin Pediatr (Phila). 2010; 50(2):106-13. DOI: 10.1177/0009922810379907. View

Liddon N, Leichliter J, Markowitz L . Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med. 2011; 42(1):44-52. DOI: 10.1016/j.amepre.2011.09.024. View

10.

Hernandez B, Wilkens L, Thompson P, Shvetsov Y, Goodman M, Ning L . Acceptability of prophylactic human papillomavirus vaccination among adult men. Hum Vaccin. 2010; 6(6):467-75. PMC: 3010761. DOI: 10.4161/hv.6.6.11279. View

11.

Elbasha E, Dasbach E . Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010; 28(42):6858-67. DOI: 10.1016/j.vaccine.2010.08.030. View

12.

Donahue K, Stupiansky N, Alexander A, Zimet G . Acceptability of the human papillomavirus vaccine and reasons for non-vaccination among parents of adolescent sons. Vaccine. 2014; 32(31):3883-5. DOI: 10.1016/j.vaccine.2014.05.035. View

13.

Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J . Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. MMWR Morb Mortal Wkly Rep. 2014; 63(29):620-4. PMC: 5779422. View

14.

Caskey R, Lindau S, Alexander G . Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health. 2009; 45(5):453-62. DOI: 10.1016/j.jadohealth.2009.04.021. View

15.

Markowitz L, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E . Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2):1-24. View

16.

Zimet G, Rosenthal S . HPV vaccine and males: issues and challenges. Gynecol Oncol. 2010; 117(2 Suppl):S26-31. DOI: 10.1016/j.ygyno.2010.01.028. View

17.

. National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010. MMWR Morb Mortal Wkly Rep. 2011; 60(33):1117-23. View

18.

Giuliano A, Palefsky J, Goldstone S, Moreira Jr E, Penny M, Aranda C . Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011; 364(5):401-11. PMC: 3495065. DOI: 10.1056/NEJMoa0909537. View

19.

Perkins R, Tipton H, Shu E, Marquez C, Belizaire M, Porter C . Attitudes toward HPV vaccination among low-income and minority parents of sons: a qualitative analysis. Clin Pediatr (Phila). 2013; 52(3):231-40. DOI: 10.1177/0009922812473775. View

20.

Darden P, Thompson D, Roberts J, Hale J, Pope C, Naifeh M . Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010. Pediatrics. 2013; 131(4):645-51. DOI: 10.1542/peds.2012-2384. View